2012
PDCD6 is an independent predictor of progression free survival in epithelial ovarian cancer
Su D, Xu H, Feng J, Gao Y, Gu L, Ying L, Katsaros D, Yu H, Xu S, Qi M. PDCD6 is an independent predictor of progression free survival in epithelial ovarian cancer. Journal Of Translational Medicine 2012, 10: 31. PMID: 22369209, PMCID: PMC3305474, DOI: 10.1186/1479-5876-10-31.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overApoptosisApoptosis Regulatory ProteinsBlotting, WesternCalcium-Binding ProteinsCarcinoma, Ovarian EpithelialCell CycleCell Line, TumorCell ProliferationDisease-Free SurvivalFemaleGene Expression Regulation, NeoplasticGene Knockdown TechniquesGene SilencingGenetic VectorsHumansKaplan-Meier EstimateLentivirusMiddle AgedNeoplasm InvasivenessNeoplasm MetastasisNeoplasms, Glandular and EpithelialOvarian NeoplasmsRNA, MessengerRNA, Small InterferingStatistics, NonparametricTransfectionConceptsEpithelial ovarian cancerProgression-free survivalOvarian cancer progressionOvarian cancer cellsOvarian cancerFree survivalOverall survivalIndependent predictorsKaplan-Meier survival analysisEpithelial ovarian cancer tissuesMetastatic ovarian cancer cellsCancer progressionPDCD6 expressionResidual tumor sizeClinical pathological factorsEpithelial ovarian cancer correlatesCancer cellsOvarian cancer correlatesOvarian cancer tissuesHistologic typeClinical progressionTumor sizeDisease stageTumor gradeCancer correlates
2009
Stathmin and tubulin expression and survival of ovarian cancer patients receiving platinum treatment with and without paclitaxel
Su D, Smith SM, Preti M, Schwartz P, Rutherford TJ, Menato G, Danese S, Ma S, Yu H, Katsaros D. Stathmin and tubulin expression and survival of ovarian cancer patients receiving platinum treatment with and without paclitaxel. Cancer 2009, 115: 2453-2463. PMID: 19322891, DOI: 10.1002/cncr.24282.Peer-Reviewed Original ResearchConceptsHigh stathmin expressionBetaIII-tubulinOvarian cancerTreatment responseOverall survivalStathmin expressionDisease progressionPaclitaxel treatmentResidual tumor sizePlatinum-based chemotherapyEpithelial ovarian cancerOvarian cancer patientsFresh tumor samplesMessenger RNA expressionBetaIII-tubulin expressionCytoreductive surgeryPatient agePolymerase chain reaction analysisPatient survivalTumor sizeDisease stagePlatinum chemotherapyPoor prognosisUnfavorable prognosisCancer patients
2006
Methylation of the insulin‐like growth factor binding protein‐3 gene and prognosis of epithelial ovarian cancer
WILEY A, KATSAROS D, FRACCHIOLI S, YU H. Methylation of the insulin‐like growth factor binding protein‐3 gene and prognosis of epithelial ovarian cancer. International Journal Of Gynecological Cancer 2006, 16: 210-218. PMID: 16445635, DOI: 10.1111/j.1525-1438.2006.00299.x.Peer-Reviewed Original ResearchMeSH KeywordsBiomarkers, TumorBiopsy, NeedleCarcinomaCohort StudiesDNA MethylationFemaleHumansImmunohistochemistryInsulin-Like Growth Factor Binding Protein 3Multivariate AnalysisNeoplasm StagingOvarian NeoplasmsOvariectomyProbabilityPrognosisProportional Hazards ModelsRetrospective StudiesRisk FactorsSensitivity and SpecificitySurvival RateConceptsIGFBP-3 promoter methylationInsulin-like growth factorIGFBP-3Disease progressionOvarian cancerGrowth factorPromoter methylationEarly-stage ovarian cancerEpithelial ovarian cancer patientsResidual tumor sizeEarly-stage diseaseIGFBP-3 expressionEpithelial ovarian cancerOvarian cancer patientsUseful prognostic markerOvarian cancer progressionIGFBP-3 promoterMethylation-specific polymerase chain reactionIGFBP-3 genePathologic variablesTumor sizeDisease stageCancer patientsPolymerase chain reactionPrognostic markerMethylation of the insulin-like growth factor binding protein-3 gene and prognosis of epithelial ovarian cancer
Wiley A, Katsaros D, Fracchioli S, Yu H. Methylation of the insulin-like growth factor binding protein-3 gene and prognosis of epithelial ovarian cancer. International Journal Of Gynecological Cancer 2006, 16: 210. DOI: 10.1136/ijgc-00009577-200601000-00034.Peer-Reviewed Original ResearchIGFBP-3 promoter methylationInsulin-like growth factorIGFBP-3Disease progressionOvarian cancerGrowth factorPromoter methylationEarly-stage ovarian cancerEpithelial ovarian cancer patientsResidual tumor sizeEarly-stage diseaseIGFBP-3 expressionEpithelial ovarian cancerOvarian cancer patientsUseful prognostic markerOvarian cancer progressionIGFBP-3 promoterMethylation-specific polymerase chain reactionIGFBP-3 genePathologic variablesTumor sizeDisease stageCancer patientsPolymerase chain reactionPrognostic marker
2004
Methylation of tumor suppressor gene p16 and prognosis of epithelial ovarian cancer
Katsaros D, Cho W, Singal R, Fracchioli S, de la Longrais I, Arisio R, Massobrio M, Smith M, Zheng W, Glass J, Yu H. Methylation of tumor suppressor gene p16 and prognosis of epithelial ovarian cancer. Gynecologic Oncology 2004, 94: 685-692. PMID: 15350359, DOI: 10.1016/j.ygyno.2004.06.018.Peer-Reviewed Original ResearchConceptsEpithelial ovarian cancerOvarian cancer prognosisOvarian cancerP16 methylationMethylation-specific PCRCancer prognosisPrimary epithelial ovarian cancerResidual tumor sizePromoter methylationRegression survival analysisOvarian cancer progressionFresh frozen tumor tissueP16 promoter methylationFrozen tumor tissueAdvanced diseaseNegative patientsOverall survivalPatient agePositive patientsPathological variablesTumor sizeDisease stageHistological gradeAggressive tumorsDisease progression
2002
Prospective Study of Eukaryotic Initiation Factor 4E Protein Elevation and Breast Cancer Outcome
Li B, Gruner J, Abreo F, Johnson L, Yu H, Nawas S, McDonald J, DeBenedetti A. Prospective Study of Eukaryotic Initiation Factor 4E Protein Elevation and Breast Cancer Outcome. Annals Of Surgery 2002, 235: 732-739. PMID: 11981220, PMCID: PMC1422500, DOI: 10.1097/00000658-200205000-00016.Peer-Reviewed Original ResearchConceptsCancer-related deathCancer recurrenceRelative riskBreast cancerIndependent predictorsReceptor statusProtein elevationHigh eIF4EMenopausal statusTumor sizeTumor gradeHigher cancer recurrence rateImportant independent prognostic markerKaplan-Meier survival curvesCox proportional hazards modelStage 1Progesterone receptor statusBreast cancer outcomesSmall retrospective studiesStage of diseaseEstrogen receptor statusCancer recurrence rateIndependent prognostic markerLog-rank testBreast cancer recurrence
1998
Insulin‐like growth factor–binding protein‐3 and breast cancer survival
Yu H, Levesque M, Khosravi M, Papanastasiou‐Diamandi A, Clark G, Diamandis E. Insulin‐like growth factor–binding protein‐3 and breast cancer survival. International Journal Of Cancer 1998, 79: 624-628. PMID: 9842972, DOI: 10.1002/(sici)1097-0215(19981218)79:6<624::aid-ijc12>3.0.co;2-9.Peer-Reviewed Original ResearchConceptsInsulin-like growth factorActions of IGFsIGFBP-3IGF-binding proteinsBreast cancer recurrenceS-phase fractionTumor sizeCancer recurrenceBreast cancerInsulin-like growth factor-binding protein-3Elevated S-phase fractionHigher IGFBP-3 levelsInhibits breast cancer cell growthBreast cancer cell growthDiagnosis-matched patientsIGFBP-3 levelsUnfavourable prognostic featuresUnfavourable prognostic indicatorPrimary breast cancerEstrogen receptor expressionLarger tumor sizeRisk of deathBreast cancer survivalCase-control studyBreast tissue extracts